Three assays show differences in binding of wild-type and mutant p53 to unique gene sequences

Technology in Cancer Research and Treatment

Volumn 8, Issue 6, 2009, Pages 445-454

  Chandrachud, Uma ^a   Gal, Susannah ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

DNA affinity immunoblotting; DNA binding; Electrophoretic mobility shift assay (EMSA); Scintillation proximity assay (SPA) beads; Streptavidin magnetic beads

Indexed keywords

CYCLIN G; CYCLINE; DNA; HYDROGEN PEROXIDE; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; STREPTAVIDIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CANCER CELL CULTURE; CONTROLLED STUDY; CYCLIN G GENE; DNA BINDING; DNA SEQUENCE; GEL MOBILITY SHIFT ASSAY; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; SCINTILLATION PROXIMITY ASSAY; THYROID CANCER; WILD TYPE;

EID: 74049103707     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460900800606     Document Type: Article

References (44)

1. Tse, G. M., Lui, P. C., Scolyer, A., Putti, T. C., Kung, F. Y., Law, B. K., Lau, T. S., Lee, C. S. Tumour Angiogenesis and p53 Protein Expression in Mammary Phyllodes Tumors. mod Pathol 16, 1007-1013 (2003).
2. Murray, J. K., Gellman, S. H. Targeting protein-protein interactions: lessons from p53/MDM2. Biopolymers 88, 657-686 (2007).
3. Rodier, F., Campisi, J., Bhaumik, D. Two faces of p53: aging and tumor suppression. Nucleic Acids Res 35, 7475-7484 (2007).
4. Liu, Y., Kulesz-Martin, M. p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. Carcinogenesis 22, 851-860 (2001).
5. Vousden, K., Lu, X. Live or let die: the cell's response to p53. Nat Rev Cancer 2, 594-604 (2002).
6. Hollstein, M., Sidransky, D., Vogelstein, B., Harris, C. C. p53 mutations in human cancers. Science 253, 49-53 (1991).
7. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1998).
8. Soussi, T., Dehouche, K., Béroud, C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum mutat 15, 105-113 (2000).
9. Vogelstein, B., Lane, D., Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
10. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
11. Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kin-zler, K., Vogelstein, B., Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9, 935-944 (1995).
12. Resnick-Silverman, L., St Clair, S., Maurer, M., Zhao, K., Manfredi, J. J. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev 12, 2102-2107 (1998).
13. Endo, Y., Fujita, T., Tamura, K., Tsuruga, H., Nojima, H. Structure and chromosomal assignment of the human cyclin G gene. Genomics 38, 92-95 (1996).
14. Okamoto, K., Beach, D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EmBO J 13, 4816-4822 (1994).
15. Wu, X., Bayle, J. H., Olson, D., Levine, A. J. The p53-mdm-2 auto-regulatory feedback loop. Genes Dev 7, 1126-1132 (1993).
16. Zauberman, A., Flusberg, D., Haupt, Y., Barak, Y., Oren, M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 23, 2584-2592 (1995).
17. Chuang, Y. Y., Chen, Y., Gadisetti, Chandramouli, V. R., Cook, J. A., Coffin, D., Tsai, W. DeGraff, M. H., Yan, H., Zhao, S., Russo, A., Liu, E. T., Mitchell, J. B. Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res 62, 6246-6254 (2002).
18. Haupt, Y., Maya, R., Kazaz, A., Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
19. Inga, A., Monti, P., Fronza, G., Darden, T., Resnick, M. A. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 20, 501-513 (2001).
20. Koga, H., Deppert, W. Identification of genomic DNA sequences bound by mutant p53 protein (Gly245->Ser) in vivo. Oncogene 19, 4178-4183 (2000).
21. Park, D. J, Nakamura, H., Chumakov, A. M., Said, J. W., Miller, C. W., Chen, D. L., Koeffler, H. P. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9, 1899-1906 (1994).
22. Kaeser, M. D., Iggo, R. D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 99, 95-100 (2002).
23. Szak, S. T., Mays, D., Pietenpol, J. A. Kinetics of p53 binding to promoter sites in vivo. mol Cell Biol 21, 3375-3386 (2001).
24. Liu, W., Konduri, S. D., Bansal, S., Nayak, B. K., Rajasekaran, S. A., Karuppayil, S. M., Rajasekaran, A. K., Das, G. M. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 281, 9837-9840 (2006).
25. Sayeed, A., Konduri, S. D., Liu, W., Bansal, S., Li, F., Das, G. M. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 67, 7746-7755 (2007).
26. Campomenosi, P., Monti, P., Aprile, A., Abbondandolo, A., Frebourg, T., Gold, B., Crook, T., Inga, A., Resnick, M. A., Iggo, R., Fronza, G. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20, 3573-3579 (2001).
27. Jagelská, E., Brázda, V., Pospisilová, S., Vojtesek, B., Palecek, E. New ELISA technique for analysis of p53 protein/DNA binding properties. J Immunol methods 267, 227-235 (2002).
28. Gal, S., Cook, J. R., Howells, L. Scintillation proximity assay for DNA binding by human p53. Biotechniques 41, 303-308 (2006).
29. Weinberg, R. L., Veprintsev, D. B., Fersht, A. R. Cooperative binding of tetrameric p53 to DNA. J mol Biol 341, 1145-1159 (2004).
30. Weinberg, R. L., Veprintsev, D. B., Bycroft, M., Fersht, A. R. Comparative binding of p53 to its promoter and DNA recognition elements. J mol Biol 348, 589-596 (2005).
31. Buzek, J., Latonen, L., Kurki, S., Peltonen, K., Laiho, M. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res 30, 2340-2348 (2002).
32. Liu, Y., Asch, H., Kulesz-Martin, M. F. Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting. Cancer Res 61, 5402-5406 (2001).
33. Ma, Y., Yuan, R., Meng, Q., Goldberg, I. D., Rosen, E. M., Fan, S. P53-independent down-regulation of Mdm2 in human cancer cells treated with adriamycin. mol Cell Biol Res Commun 3, 122-128 (2000).
34. Okumura, N., Saji, S., Eguchi, H., Hayashi, S., Saji, S., Nakashima, S. Estradiol stabilizes p53 protein in breast cancer cell line, MCF-7. Jpn J Cancer Res 93, 867-873 (2002).
35. Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., Koeffler, H. P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91, 179-184 (1993).
36. Cho, Y., Gorina, S., Jeffrey, P. D., Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355 (1994).
37. Concin, N., Zeillinger, C., Tong, D., Stimpfl, M., König, M., Printz, D., Stonek, F., Schneeberger, C., Hefler, L., Kainz, C., Leodolter, S., Haas, O. A., Zeillinger, R. Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat 79, 37-46 (2003).
38. Ko, L. J., Prives, C. p53: puzzle and paradigm. Genes Dev 10, 1054-1072 (1996).
39. Müller-Tiemann, B. F., Halazonetis, T. D., Elting, J. J. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc Natl Acad Sci USA 95, 6079-6084 (1998).
40. Moll, U. M., Slade, N. p63 and p73: roles in development and tumor formation. mol Cancer Res 2, 371-386 (2004).
41. Frasca, F., Vella, V., Aloisi, A., Mandarino, A., Mazzon, E., Vigneri, R., Vigneri, P. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 63, 5829-5837 (2003).
42. Leong, C., Vidnovic, N., DeYoung, M., Sgroi, D., Ellisen, L. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117, 1370-1380 (2007).
43. Wei, C. L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., Liu, J., Zhao, X. D., Chew, J. L., Lee, Y. L., Kuznetsov, V. A., Sung, W. K., Miller, L. D., Lim, B., Liu, E. T., Yu, Q., Ng, H. H., Ruan, Y. A global map of p53 transcription-factor binding sites in the human genome. Cell 124, 207-219 (2006).
44. Nordhoff, E, Krogsdam, A. M, Jørgensen, H. F, Kallipolitis, B. H, Clark, B. F, Roepstorff, P, Kristiansen, K. Rapid identification of DNA-binding proteins by mass spectrometry, Nat Biotechnol 17, 884-888 (1999).